Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACHV vs TYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHV Captures Overall Composite Edge (56.6 HOLD vs 32.4 SELL), While TYRA Leads 3–2 on Growth & Valuation Pillars

ACHV Overall Winner 6-Pillar Tally: ACHV 2 – 3 TYRA (1 Tie) Matrix Metrics: ACHV 4 – 3 TYRA

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Tyra Biosciences, Inc. (TYRA) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.4/100 SELL) after splitting the core matrix 4–3 (led by Valuation Multiples, Options & Positioning), while TYRA wins 3–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus TYRA at $20.18 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. TYRA 32.4/100 SELL) and 1.73β · 62% Vol risk profile, whereas TYRA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile TYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACHV vs TYRA
ACHV NASDAQ Head-to-Head Winner
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28
TYRA NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$20.18
+0.77% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.79β · 49% Vol
Unified Composite Score
32.4 / 100 SELL
Tech 25.0 Fund 46.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $20.94 · SMA50: $21.57

6-Pillar Scorecard Institutional Category Breakdown (ACHV 2 – 3 TYRA)

Columns: Metric · ACHV · TYRA
1. Valuation Multiples ACHV
Forward P/E 35.3x N/M
Trailing P/E 35.3x N/M
PEG Ratio 17.68x N/M
EV / Revenue N/M N/M
2. Growth & Scale TYRA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $692.8M $1.3B
3. Profitability & Quality TYRA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -845.0% -34.9%
4. Balance Sheet & Cash Flow TYRA
Cash Generation (TTM) -$44M -$120M
Cash Flow Margin N/A N/A
Net Cash / Leverage $46M Net Cash $451M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 88.3% (23rd %ile) 69.0% (3rd %ile)
Put/Call OI Skew N/A 12.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACHV (4) vs TYRA (3)
Institutional Metric ACHV TYRA Criterion Row Edge
Market Capitalization
Scale
$692.8M $1.3B Larger Scale TYRA
Trailing P/E Ratio
Valuation
35.3x N/M Lower Multiple ACHV
Forward P/E Ratio
Valuation
35.3x N/M Lower Multiple ACHV
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-845.0% -34.9% Higher ROE TYRA
52-Week Range Position
Momentum
69% ($3–$9) 21% ($15–$41) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.73β · 62% Vol 0.79β · 49% Vol Lower Realized Risk TYRA
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 32.4 / 100 (SELL) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.68x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($46M Net Cash) -$120M ($451M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TYRA +20.34 pp
ACHV: -8.5% · TYRA: +11.84%
3M Horizon ACHV +11.59 pp
ACHV: +0.15% · TYRA: -11.44%
6M Horizon ACHV +55.72 pp
ACHV: +21.29% · TYRA: -34.43%
1Y Horizon ACHV +4.99 pp
ACHV: +48.03% · TYRA: +43.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs TYRA. Trailing 12-month operating profitability (ACHV 0.0% vs TYRA 0.0%) and valuation multiples (ACHV 35.3x vs TYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x
TYRA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TYRA BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 69.0%
IV Percentile 3rd %ile
Put/Call OI Skew 12.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACHV vs TYRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Tyra Biosciences, Inc. (TYRA) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.4/100 SELL) after splitting the core matrix 4–3 (led by Valuation Multiples, Options & Positioning), while TYRA wins 3–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus TYRA at $20.18 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. TYRA 32.4/100 SELL) and 1.73β · 62% Vol risk profile, whereas TYRA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile TYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TYRA leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TYRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus N/A for TYRA. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TYRA.

ACHV screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas TYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus TYRA (-34.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, TYRA carries 69.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 12.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.79β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.